Mirati Therapeutics Inc

+3.12 (+1.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)8.78B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.15 Million
Adjusted EPS-$2.13
See more estimates
10-Day MA$171.77
50-Day MA$190.17
200-Day MA$181.44
See more pivots

Mirati Therapeutics, Inc. Stock, NASDAQ:MRTX

9393 Towne Centre Drive, Suite 200, San Diego, California 92121
United States of America
Phone: +1.858.332.3410
Number of Employees: 111


Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.